Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Income from Continuing Operations came in at 69005000.0 in Q1 2026, down 54.12% YoY from 150409467.16 in Q1 2025, and down 10.36% on a QoQ basis from 62530000.0 in Q4 2025.
Powered by 
Analysis
Spyre Therapeutics (SYRE) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Income from Continuing Operations data on file, last reported at 69005000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 54.12% year-over-year to 69005000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 179435000.0 (up 14.12% YoY) and the FY2025 annual result came in at 155203000.0, up 25.39% from the prior year.
- Income from Continuing Operations eased to 69005000.0 in Q1 2026, from 62530000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 11183000.0 in Q3 2025 to a low of 217081000.0 in Q2 2023.
- A 5-year average of 50284176.47 and a median of 40107000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 872.45% — and 2025, when it surged 83.8%.
- Tracing SYRE's Income from Continuing Operations over 5 years: stood at 18822000.0 in 2022, then slumped by 235.67% to 63180000.0 in 2023, then advanced by 10.9% to 56296000.0 in 2024, then decreased by 11.07% to 62530000.0 in 2025, then dropped by 10.36% to 69005000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 69005000.0 (Q1 2026), 62530000.0 (Q4 2025), and 11183000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Spyre Therapeutics | 7.35 Bn | 7.35 Bn | - | -36.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.20 Mn |
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.77 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.03 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.86 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.11 Mn |
| Jun 30, 2023 | -217.08 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -22.32 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.45 Mn |
| Sep 30, 2021 | -20.31 Mn |